MEGAPTH Dosage/Direction for Use

Route of administration: Subcutaneous Injection.
Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: The recommended dose is 20 mcg subcutaneously once a day.
Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture: The recommended dose is 20 mcg subcutaneously once a day.
Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture: The recommended dose is 20 mcg subcutaneously once a day.
Administration: Teriparatide (rDNA origin) injection should be administered as a subcutaneous injection into the thigh or abdominal wall. There are no data available on the safety or efficacy of intravenous or intramuscular injection of teriparatide (rdna origin) injection.
Teriparatide (rDNA origin) injection should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Teriparatide (rDNA origin) injection is a clear and colorless liquid. Do not use if solid particles appear or if the solution is cloudy or colored.
Patients and caregivers who administer Teriparatide (rDNA origin) injection should receive appropriate training and instruction on the proper use of the Teriparatide (rDNA origin) injection delivery device from a qualified health professional.
Pediatric: There is no experience in children. rhPTH (1-34) (teriparatide for injection) should not be used in pediatric patients or young adults with open epiphyses.
Geriatric: Dosage adjustment based on age is not required.
MISSED DOSE: If the patient misses a dose, use it as soon as remembered. If it is near the time of the next dose, skip the missed dose and resume the usual dosing schedule. Do not double the dose to catch up.
Treatment Duration: The safety and efficacy of Teriparatide (rDNA origin) injection have not been evaluated beyond 2 years of treatment. Consequently, use of the drug for more than 2 years during a patient's lifetime is not recommended.